Search research articles
Contact Us
Filters
Showing results (31-40 of 244) with videos related to
Page
of 25
Sort By:
Journal of Crohn'S & Colitis
|
August 13, 2014
Temporal trends in non-stricturing and non-penetrating behaviour at diagnosis of Crohn's disease in Örebro, Sweden: a population-based retrospective study
Yaroslava Zhulina, Ruzan Udumyan, Ida Henriksson, et al.
Scandinavian Journal of Gastroenterology
|
August 21, 2020
Genetic and shared environmental risk factors do not lead to eosinophil activation in healthy twins of IBD patients
Jonas Halfvarson, Maria Ling Lundström, Maria Lampinen, et al.
Alimentary Pharmacology & Therapeutics
|
February 10, 2021
Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game-authors' reply
Sara Rundquist, Michael C Sachs, Carl Eriksson, et al.
Lakartidningen
|
December 17, 2009
[Current drug therapy in Crohn disease--national guidelines]
Sven Almer, Ragnar Befrits, Anders S Eriksson, et al.
The American Journal of Gastroenterology
|
August 8, 2007
Long-term colectomy rate after intensive intravenous corticosteroid therapy for ulcerative colitis prior to the immunosuppressive treatment era
Anders Gustavsson, Jonas Halfvarson, Anders Magnuson, et al.
Alimentary Pharmacology & Therapeutics
|
December 19, 2020
Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers
Sara Rundquist, Michael C Sachs, Carl Eriksson, et al.
Alimentary Pharmacology & Therapeutics
|
April 8, 2021
Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. Authors' reply
Sara Rundquist, Michael C Sachs, Carl Eriksson, et al.
BMC Gastroenterology
|
June 8, 2023
Epidemiology, validation, and clinical characteristics of inflammatory bowel disease: the ABIS birth cohort study
Malin Östensson, Olle Björkqvist, Annie Guo, et al.
Alimentary Pharmacology & Therapeutics
|
April 23, 2022
Age determines the risk of familial inflammatory bowel disease-A nationwide study
Jonas Halfvarson, Jonas F Ludvigsson, Francesca Bresso, et al.
Journal of Digestive Diseases
|
November 24, 2018
Differential clustering of fecal and mucosa-associated microbiota in 'healthy' individuals
Adam Carstens, Annika Roos, Anna Andreasson, et al.
Page
of 25
Search research articles
Search
Showing results (31-40 of 244) with videos related to
Sort By:
Page
of 25
Journal of Crohn'S & Colitis
|
August 13, 2014
Temporal trends in non-stricturing and non-penetrating behaviour at diagnosis of Crohn's disease in Örebro, Sweden: a population-based retrospective study
Yaroslava Zhulina, Ruzan Udumyan, Ida Henriksson, et al.
Scandinavian Journal of Gastroenterology
|
August 21, 2020
Genetic and shared environmental risk factors do not lead to eosinophil activation in healthy twins of IBD patients
Jonas Halfvarson, Maria Ling Lundström, Maria Lampinen, et al.
Alimentary Pharmacology & Therapeutics
|
February 10, 2021
Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game-authors' reply
Sara Rundquist, Michael C Sachs, Carl Eriksson, et al.
Lakartidningen
|
December 17, 2009
[Current drug therapy in Crohn disease--national guidelines]
Sven Almer, Ragnar Befrits, Anders S Eriksson, et al.
The American Journal of Gastroenterology
|
August 8, 2007
Long-term colectomy rate after intensive intravenous corticosteroid therapy for ulcerative colitis prior to the immunosuppressive treatment era
Anders Gustavsson, Jonas Halfvarson, Anders Magnuson, et al.
Alimentary Pharmacology & Therapeutics
|
December 19, 2020
Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers
Sara Rundquist, Michael C Sachs, Carl Eriksson, et al.
Alimentary Pharmacology & Therapeutics
|
April 8, 2021
Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. Authors' reply
Sara Rundquist, Michael C Sachs, Carl Eriksson, et al.
BMC Gastroenterology
|
June 8, 2023
Epidemiology, validation, and clinical characteristics of inflammatory bowel disease: the ABIS birth cohort study
Malin Östensson, Olle Björkqvist, Annie Guo, et al.
Alimentary Pharmacology & Therapeutics
|
April 23, 2022
Age determines the risk of familial inflammatory bowel disease-A nationwide study
Jonas Halfvarson, Jonas F Ludvigsson, Francesca Bresso, et al.
Journal of Digestive Diseases
|
November 24, 2018
Differential clustering of fecal and mucosa-associated microbiota in 'healthy' individuals
Adam Carstens, Annika Roos, Anna Andreasson, et al.
Page
of 25